187 related articles for article (PubMed ID: 25724377)
1. A Potential Epigenetic Therapy for NSCLC.
Cancer Discov; 2015 Apr; 5(4):341. PubMed ID: 25724377
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
3. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
Fillmore CM; Xu C; Desai PT; Berry JM; Rowbotham SP; Lin YJ; Zhang H; Marquez VE; Hammerman PS; Wong KK; Kim CF
Nature; 2015 Apr; 520(7546):239-42. PubMed ID: 25629630
[TBL] [Abstract][Full Text] [Related]
4. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
5. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
Barsotti AM; Ryskin M; Rollins RA
Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
[No Abstract] [Full Text] [Related]
7. Developing EZH2-Targeted Therapy for Lung Cancer.
Frankel AE; Liu X; Minna JD
Cancer Discov; 2016 Sep; 6(9):949-52. PubMed ID: 27587466
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
9. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
10. Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.
Pasini A; Delmonte A; Tesei A; Calistri D; Giordano E
Drugs; 2015 Oct; 75(15):1757-71. PubMed ID: 26347133
[TBL] [Abstract][Full Text] [Related]
11. New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer.
Forde PM; Brahmer JR; Kelly RJ
Clin Cancer Res; 2014 May; 20(9):2244-8. PubMed ID: 24644000
[TBL] [Abstract][Full Text] [Related]
12. Activation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cells.
Wu J; Zhao S; Tang Q; Zheng F; Chen Y; Yang L; Yang X; Li L; Wu W; Hann SS
J Exp Clin Cancer Res; 2015 Sep; 34(1):99. PubMed ID: 26362062
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer.
Verma SK
Curr Top Med Chem; 2015; 15(8):714-9. PubMed ID: 25732793
[TBL] [Abstract][Full Text] [Related]
14. Targeted epigenetic therapies: the next frontier?
Tuma RS
J Natl Cancer Inst; 2010 Dec; 102(24):1824-5. PubMed ID: 21139098
[No Abstract] [Full Text] [Related]
15. How should "RET positive" NSCLC be treated?
Smit EF
Lung Cancer; 2017 Jun; 108():250-251. PubMed ID: 28189265
[No Abstract] [Full Text] [Related]
16. The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2.
Li Z; Xu L; Tang N; Xu Y; Ye X; Shen S; Niu X; Lu S; Chen Z
FEBS Lett; 2014 Aug; 588(17):3000-7. PubMed ID: 24928441
[TBL] [Abstract][Full Text] [Related]
17. VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach.
Barr MP; O'Byrne KJ; Al-Sarraf N; Gray SG
Epigenomics; 2015; 7(6):897-910. PubMed ID: 26479311
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.
Zhang H; Qi J; Reyes JM; Li L; Rao PK; Li F; Lin CY; Perry JA; Lawlor MA; Federation A; De Raedt T; Li YY; Liu Y; Duarte MA; Zhang Y; Herter-Sprie GS; Kikuchi E; Carretero J; Perou CM; Reibel JB; Paulk J; Bronson RT; Watanabe H; Brainson CF; Kim CF; Hammerman PS; Brown M; Cichowski K; Long H; Bradner JE; Wong KK
Cancer Discov; 2016 Sep; 6(9):1006-21. PubMed ID: 27312177
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]